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Abstract
 .A cDNA clone encoding rat p130, a member of the retinoblastoma Rb gene family, was isolated based on the sequence
homology of the E1A-binding domain. The 4.87 kb cDNA contained an 1135-amino acid open reading frame with high
homologies to the human and mouse p130 and a partial homology to the pRb protein. p130 showed difference in
distribution of potential phosphorylation sites from pRb in the N-terminal and the B pocket regions. p130 mRNA was
detected in most rat tissues. The p130 gene was mapped to rat chromosome 19p11-13 by fluorescence in situ hybridization.
q 1997 Elsevier Science B.V.
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The adenovirus E1A proteins play an important
role in the early stage of adenovirus infection and
w xgrowth regulation of transformed cells 1,2 . E1A
protein has been shown to interact with several cellu-
w xlar proteins 3,4 . Correlation between regions of the
E1A protein required for transformation and those for
interactions with particular cellular proteins suggests
that these interactions underlie the mechanism of the
w xtransforming functions of E1A 5–8 . E1A is also
able to block terminal differentiation of certain estab-
w xlished cell lines 9,10 . Among the E1A associated
) Corresponding author. Fax: q81 11 6153099. E-mail:
ysawada@sapmed.ac.jp
cellular proteins, pRb the product of the retinoblas-
. w xtoma tumor suppressor gene 11 , pRb-related p107
w x w x12 and p130 13–15 form a family of related
proteins sharing homologous E1A-binding regions,
so-called pocket regions. The growth suppressive
properties of pRb are likely mediated mostly through
interaction and modulation of the activity of tran-
scription factors involved in cell cycle progression
w xand cell differentiation 16 . p130 also is capable of
arresting cells in the G1 phase of the cell cycle when
expressed ectopically in the otherwise growing cells
w x17 . As a step to analyze possible roles of rat p130 in
adenoviral transformation and cell cycle regulation of
rat cells, we have isolated a cDNA for the rat p130
that shares characteristic features of the Rb gene
family.
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Fig. 2. Northern analysis of rat p130 mRNA. Total cellular RNA was isolated from cultured rat cells and adult rat tissues by a
w xguanidinium-CsCl method 38 . Ten mg of RNA were run on a 1% formaldehyde-agarose gel, blotted to a nylon membrane, and probed
32  .with P-labeled rat p130 cDNA. mRNA for rat glucose 3-phosphate dehydrogenase G3PDH was also detected using a specific
hybridization probe as an internal control of RNA quantity. Relative signal intensity of p130 mRNA was obtained by analysing
 .autoradiograms with an image analysing software NIH image and is given in parenthesis following each RNA source in arbitrary unit
 .  .  .  .  .after normalization against that of G3PDH mRNA: 1, liver 1.08 ; 2, spleen 3.05 ; 3, kidney 1.34 ; 4, intestine 1.40 ; 5, brain 1.18 ; 6,
 .  .  .  .  .  .heart 0.96 ; and 7, thymus 2.56 of adult rat, and 8, L-2 0.79 ; 9, NRK49F 1.25 ; 10, B5-4 1.57 ; 11, 5YC2 1.19 ; and 12, YNI-3
 .1.00 cell lines. B5-4 and 5YC2 are BRK and 3Y1 cells, respectively, transformed with p5XhoC containing Ad5 E1A plus E1B genes.
YNI-3 is 3Y1 cells transformed with p5A12-NI containing Ad12-Ad5 chimeric E1A plus Ad5 E1B genes.
Among the amino acid sequences of human pRb
w x w x w x w x18 , p107 12 , p130 13–15 and mouse pRb 19
available at the beginning of this study, two hexapep-
tide sequences, FYKVIE in the A pocket and
DRHLDQ in the B pocket region, were conserved
w x X15 . To minimize mismatches in the 3 region of the
oligonucleotide primers, the nucleotide sequences of
w xhuman p130 13 encoding the peptide sequences
PHYHFYKV and HLDQLLM were used to design
 . Xsense and antisense primers, SK 5 -CAG GTA CCT
X  .CTT TAT CAT TTT TAT AAG GT-3 and UH
5X-TCA AGC TTC ATT AAT AAC TGG TCC AGA
TG-3X, respectively. The 5X ends contained 6 and 8
additional nucleotides providing two restriction sites
 .Kpn I and Hin dIII, respectively that were used for
subcloning of the amplified PCR fragments in a
 .pBluescript vector Stratagene . Total cellular RNAs
w xfrom rat cells including FRTL-5 cells 20 and human
placenta were used as templates for RT-PCR reac-
tions. A predominant PCR product of 1 Kb was
generated on each template. Sequencing of the PCR
product revealed an open reading frame with an
encoded amino acid sequence highly homologous
 .90% to human p130 but less homologous to human
p107 or pRb. This PCR product was used as a probe
to screen a lgt10 spleen cDNA library Sprague-
.Dawley rat; Clontech . Nine positive clones were
obtained and six of them were found to contain
overlapping subregions of the same cDNA sequence.
Three of them, after compilation, represented a 3.65
kb insert with an open reading frame from the 5X end
to 300 nucleotides upstream of the 3X end.
Additional 5X sequences were generated with a 5X
 .RACE rapid amplification of cDNA ends reaction
 . Xkit Clontech using the nested primers 5 -CTG GTT
CGG CCC ACC TCT GAA GGT TCC AGA ATC
GAT AG-3X, 5X-AGG AAT TCG AAC CGC TGT
TGG ATC TG-3X, and 5X-TCG TCC ATG TTA AGG
CGG CTG CAC AG-3X to amplify the same cDNA
library. Several clones of the 5X RACE reaction prod-
Fig. 1. Nucleotide sequence of rat p130 cDNA and deduced amino acid sequence. The coding strand of the p130 cDNA is shown. Amino
acid sequence of the open reading frame is shown below beginning at the first methionine and continuing until the first termination codon
). located at nucleotide 3472.
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uct were sequenced and found to be identical except
for variability between G and T at nucleotide 54 and
between A and G at nucleotide 192. Consensus of
them represented an additional 130 nucleotides to the
5X end of previously isolated cDNA sequences and
probably represents most, if not all, of the 5X mRNA
sequences including the translational initiation site.
Additional 3X sequences were also generated with a 3X
RACE method using the nested primers 5X-CAG GAG
GAA ACT ATC TTC AC-3X, 5X-GAG GTT CAC
CTG AGG TTA G-3X, and 5X-AGT CCA AGC TGA
ATT CCG GTT T-3X to amplify the cDNA library.
The reaction product extended the 3X noncoding se-
quence by 1016 nucleotides. Both strands of the
cDNA were sequenced using the dideoxy chain ter-
mination method. The resulting composite cDNA was
4.87 kb and encoded an open reading frame of 1135
 .amino acids beginning with an AUG Fig. 1 . The
start codon was preceded by 66 nucleotides of un-
translated 5X-flanking sequences, which include an
 .in-frame stop codon Fig. 1 . The cDNA also in-
cluded 1401 nucleotides of 3X-untranslated sequences.
Based on the high homology to human p130 through
 .the whole coding sequence Fig. 3 , we concluded
that our cDNA is the rat p130 cDNA. It also has a
w xhigh homology to the mouse homolog 21–23 re-
ported during the preparation of this manuscript.
Northern analysis of total cellular RNA from sev-
eral rat cell lines and tissues detected a doublet of
mRNA species of approximately 4.8-5.0 kb, the same
 .size as the p130 cDNA Fig. 2 . This indicated that
our cDNA represents most, if not all, of the rat p130
mRNA. Although the rat p130 mRNA was shown to
be expressed constitutively in many tissues, adult
tissues such as spleen and thymus were found to
express high levels of p130 mRNA, while tissues
such as liver, kidney, intestine, brain and heart ex-
 .pressed lower levels of p130 mRNA Fig. 2 . The
level of p130 mRNA in transformed cells that ex-
press a chimeric E1A between type 12 and type 5
 .YNI-3 was essentially the same as in cells that
 .  .express adenovirus type 5 E1A 5YC2 Fig. 2 .
Comparison of the rat p130 sequence with the
sequences of rat pRb and human p130 confirmed that
these proteins are related as shown in Fig. 3. There is
extensive sequence homology, 90% of identity, be-
tween the predicted amino acid sequences of the rat
and human p130 throughout most of the reading
frame of these proteins. Homology between the rat
p130 and the rat pRb is rather limited mainly to the
pocket regions. Within this regions 113 of 356 amino
acid residues are identical between the rat p130 and
pRb proteins, making 32% of identity. The sequence
data also suggest differences in possible phosphoryla-
tion sites between pRb and p130 proteins that may be
involved in the functional regulation. In the rat, mouse
and human pRb sequences, ten potential phosphoryla-
tion sites of cyclin dependent protein SerrThr ki-
 .  .nases CDKs -X-SrT-P-X-KrR- which seem to
regulate the function of pRb are completely con-
served: four in the N-terminal region, one in the
w xspacer region and five in the C-terminal region 24 .
These are indicated in Fig. 3 with two more possible
sites that match the above consensus. p130 protein
does not have potential phosphorylation sites for
 .those kinases in the N-terminal region Fig. 3 . On
the other hand, p130 has an additional potential
phosphorylation site for cyclic adenosine monophos-
 .phate cAMP -dependent protein kinase, close to the
conserved phosphorylation site for casein kinase II
 .CK2 in the extreme N-terminal region. Since cAMP
induces G1 phase arrest in some types of cells and it
is mediated, at least in part, by a CDK inhibitor
kip1 w xp27 25 , it would be important to examine whether
or not p130 and p107 are involved and play a role in
the cAMP signal transduction pathway. p130 also
differs from pRb by having an additional potential
phosphorylation site of CK2 in the B pocket region
 .Fig. 3 . It is pointed out that there is a unique RGD
 .arginine-glycine-aspartic acid sequence which could
be a target of binding for the integrin family of
receptors within the B pocket region of p130. These
characteristic features on the amino acid sequence
suggest that p130 and pRb proteins may be subject to
Fig. 3. Comparison of rat p130 with human p130 and rat pRb. A comparison of the amino acid sequence of rat p130 with human p130
w x w x13 and rat pRb protein 24 is shown. Dotts represent identical amino acids and bars indicate gaps. Asterisks emphasize identical amino
acids among the three proteins. Regions corresponding to the A and B pocket regions are boxed by dotted lines and indicated as A and B.
Consensus recognition sites for CDKs are boxed, and potential phosphorylation sites for CK2 and for cAMP-dependent protein kinase are
underlined. An RGD motif is also underlined.
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different regulation through phosphorylation in the
N-terminal and the B pocket regions.
To confirm that the protein encoded by our p130
cDNA is capable of binding to E1A, in vitro-synthe-
sized p130 was tested for its ability to bind to E1A. A
3.5 kb cDNA which contained the entire open read-
 .ing frame ORF produced a translation product mi-
grating at about 130 kD in in vitro
 .transcriptionrtranslation reactions Fig. 4A . The ra-
dioactively labeled in vitro-translated p130 was incu-
 .bated with glutathione S transferase GST -E1A fu-
sion proteins containing the amino acid residues 27–
134 of type 12 E1A or 22–116 of type 5 E1A. These
 .portions of E1A include the conserved region 1 CR1
and CR2 regions of E1A, which have been shown to
be sufficient for interaction with the Rb family pro-
w xteins 26 . The results in Fig. 4B show that the in
vitro translated rat p130 was capable of binding to
both type 5 and type 12 E1A proteins. A mutation
 .44,45KL within the pRb binding sequence of the
CR1 region had only a slight effect in agreement with
w xthe previous results 15 .
The chromosomal localization of the rat p130 gene
was determined by fluorescence in situ hybridization
 .FISH using biotin-labeled rat p130 cDNA to probe
metaphase chromosomes from rat splenocytes. The
majority of the metaphases examined showed specific
labeling of at least one pair of sister chromatids. In
many metaphases, the sister chromatids of both ho-
mologous chromosomes were labeled. In all cases,
signal was confined to a small chromosome which
 .was identified as chromosome 19p11–13 Fig. 5 , a
w xregion syntenic with mouse chromosome 8 27 and
w xhuman chromosome 16q 28 where the human p130
gene is localized around chromosomal band q12.2
w x13,14,29 . This confirms and refines the previous
 .Fig. 4. Complex formation of in vitro translated rat p130 with adenovirus E1A. A A portion of the rat p130 cDNA containing the entire
 .  .  .  .ORF was recloned into pBluescript II KS q Stratagene . After linearization with Sal I lane 3 or ClaI lane 4 , complementary RNA
was transcribed using T7 RNA polymerase, and subsequently translated in vitro in a TNT coupled rabbit reticulocyte lysate system
 . w35 x  .  .Promega in the presence of S methionine. Control reactions contained no DNA lane 1 or vector plasmid lane 2 . The reaction
 .products were separated on an SDS-PAGE and detected by autoradiography. B DNA fragments of type 12 and type 5 E1A genes
 .containing CR1 and CR2 regions were cloned into pGT-3 and pGT-2, derivatives of pGEX-2T Pharmacia . GST-E1A fusion proteins
w x  .  .were expressed and purified as described 39 . p130 was recovered by binding to fusion proteins of type 12 lane 7 and of type 5 lane 9
 .  .E1A. A mutant E1A protein of type 12 with an alteration in CR1 was also used lane 8 . Reaction products with no DNA lanes 1-3 or
 .  .  .vector plasmid lanes 4-6 were also assayed with fusions of type 12 E1A lanes 1 and 4 , mutant type 12 E1A lanes 2 and 5 and type 5
 .E1A lanes 3 and 6 .
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 .Fig. 5. Chromosomal localization of rat p130 gene. Fluorescence in situ hybridization FISH was carried out with biotinylated rat p130
w x w xcDNA probe as described previously 40 . BrdU-synchronized rat splenocytes metaphase spreads were prepared as described 41 and
 .hybridized with the DNA probe. The slides were incubated with FITC-conjugated avidin DCS Vector Labs. , amplified by incubation
 .with biotin-labeled goat anti-avidin D antibody Vector Labs. , followed by a second incubation with FITC-conjugated avidin DCS.
 .  .Preparations were counterstained with propidium iodide PI and examined in a laser scanning microscope Zeiss LSM . Arrows indicate
 .positive signals on the short arm of R-banded rat chromosome 19 19p11-13 . Ideogram of G-banded chromosome 19 and the location of
p130 gene are shown on the right.
data that mapped the p130 gene on chromosome 19
by Southern blot analysis of a panel of somatic cell
w xhybrids using human p130 cDNA as a probe 29 .
The Rb family proteins are capable of forming
complexes with the E2F family of transcription fac-
tors that have been implicated in the control of a
number of genes whose expression is critical for cell
growth. Complexes between E2F and pRb can sup-
w xpress transcription when bound to E2F sites 30 .
Upon phosphorylation of pRb, pRb-E2F complexes
dissociate and the released E2F can then activate
w xtranscription 31,32 . Recent studies have revealed
that p130 exerts a growth suppressive function
through interaction with the E2F transcription factors
and that p130 and pRb interact functionally with
w xdifferent members of the E2F family 33,34 . p130
also is a phosphoprotein and its phosphorylation state
is regulated in a cell cycle-dependent manner
w x13,35,36 . The fact that p130 can interact with G1
w xcyclin-CDK complexes 13,14,37 would be, at least
in part, a mechanistic basis of the cell cycle depen-
dent phosphorylation of p130.
The present study will provide a cognate tool for
further analyses of the p130 functions in rat cells in
vivo and in vitro.
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